Eosinophilic esophagitis in Sri Lanka: Symptoms, Causes & Treatment | aihealz
ICD variantEosinophilic esophagitis is a specific ICD-10 coded subtype of Eosinophilic Esophagitis. The clinical content below covers Eosinophilic Esophagitis in general.
GastroenterologymoderateICD-10 · K20.0
Eosinophilic esophagitis.Care & specialists in Sri Lanka
In Sri Lanka, eosinophilic esophagitis is managed by gastroenterologists. Eosinophilic esophagitis (EoE) is a chronic, immune-mediated inflammation of the esophagus driven by type-2 allergic responses to food and aeroallergens, with eosinophils invading a tissue that normally has none. It affects roughly 1 in 2,000 adults and children in North America and Europe — prevalence has risen more than tenfold over 25 years, faster than any other chronic GI disease.
aliases · Eosinophilic Esophagitis (EoE — allergic inflammation of the swallowing tube)· इओसिनोफिलिक इसोफैजाइटिस· Œsophagite à éosinophiles· reviewed May 12, 2026
EB
Reviewed by AIHealz Medical Editorial Board · GastroenterologyLast reviewed May 12, 2026
Eosinophilic esophagitis (ICD-10: K20.0) is a chronic, type-2 immune-mediated disease defined by symptoms of esophageal dysfunction plus dense eosinophilic inflammation isolated to the esophagus, with at least 15 eosinophils per high-power field on biopsy after secondary causes are excluded. The 2018 AGREE international consensus dropped the previous requirement of a PPI trial before diagnosis — PPI-responsive eosinophilia is now considered part of the EoE spectrum, not a separate entity. Pathogenesis is driven by food and aeroallergen exposure in genetically predisposed individuals, which triggers a Th2 cytokine cascade involving interleukin-5, interleukin-13, and thymic stromal lymphopoietin. Eosinophils, mast cells, and T cells infiltrate the esophageal mucosa and submucosa, releasing granule proteins and TGF-beta.
key facts
Prevalence
~1 in 2,000 adults in the US and Europe; ~57 per 100,000 population (Dellon 2018 meta-analysis)
Demographics
Male predominance ~3:1; 70-80% have a personal history of atopy (asthma, allergic rhinitis, atopic dermatitis, food allergy)
Avg. age
Two peaks — children age 5-10 with feeding problems; adults age 20-40 with dysphagia and food impaction
Global cases
Rising globally; most common cause of food impaction in adults under 50
Specialist
Gastroenterology
ICD-10
K20.0
§ 02
How you might notice it
The key symptoms of Eosinophilic esophagitis are: Slowly progressive solid-food dysphagia — patients describe food sticking, taking longer to eat, drinking more water with meals, and learning to chew thoroughly or avoid dry meats and breads (the so-called 'IMPACT' adaptive behaviors)., Recurrent food impaction in which a piece of meat, bread, or rice obstructs the esophagus and requires emergency endoscopy to remove — EoE is the cause of roughly 50% of adult food impactions presenting to emergency departments., Heartburn or chest discomfort that often does not fully respond to a standard course of acid-suppressing medication, prompting endoscopy that uncovers EoE., Odynophagia (painful swallowing), especially after dry, coarse, or temperature-extreme foods., In children, feeding refusal, prolonged meal times, food selectivity (eating only soft or smooth textures), vomiting after meals, abdominal pain, and failure to thrive., Regurgitation of undigested food shortly after eating, sometimes confused with classic acid reflux., Nocturnal cough or aspiration episodes when retained food refluxes during sleep..
01Slowly progressive solid-food dysphagia — patients describe food sticking, taking longer to eat, drinking more water with meals, and learning to chew thoroughly or avoid dry meats and breads (the so-called 'IMPACT' adaptive behaviors).
02Recurrent food impaction in which a piece of meat, bread, or rice obstructs the esophagus and requires emergency endoscopy to remove — EoE is the cause of roughly 50% of adult food impactions presenting to emergency departments.
03Heartburn or chest discomfort that often does not fully respond to a standard course of acid-suppressing medication, prompting endoscopy that uncovers EoE.
§ 03
How it’s diagnosed
diagnosis
Diagnosis requires two criteria together: symptoms of esophageal dysfunction (dysphagia, food impaction, heartburn, feeding problems in children) and at least 15 eosinophils per high-power field on esophageal biopsy. Endoscopy with biopsy is the only way to make the diagnosis — no blood test, scan, or symptom score replaces it. The 2018 AGREE consensus removed the prior requirement of a 6-8 week PPI trial before diagnosis: patients now receive the EoE label on biopsy alone, and PPI is reframed as a first-line treatment rather than a diagnostic test. At endoscopy the clinician inspects for the EREFS findings — edema, fixed rings, exudates, furrows, and strictures (Hirano 2013 score) — and takes at least six biopsies from the proximal and distal esophagus, since eosinophil distribution can be patchy. Other causes of esophageal eosinophilia must be excluded, including reflux disease, eosinophilic gastroenteritis with esophageal involvement, achalasia, Crohn's disease, hypereosinophilic syndrome, drug hypersensitivity, infection, and connective-tissue disease. Allergy testing (skin prick, specific IgE, atopy patch testing) does not reliably identify EoE food triggers and is not recommended to guide elimination diets. The 2020 AGA/JTF joint clinical guideline recommends repeat endoscopy after 8-12 weeks of any new therapy to confirm histologic remission, because symptom improvement does not always correlate with disappearance of eosinophilic inflammation. Esophageal narrowing should be evaluated by careful inspection during endoscopy or by a barium esophagram with a 13 mm tablet challenge if a subtle stricture is suspected.
Key tests
01
Upper endoscopy with esophageal biopsies (EGD with EREFS scoring)The diagnostic gold standard. Identifies typical features (rings, furrows, exudates, edema, strictures) and provides tissue for histology. Six or more biopsies are taken from proximal and distal esophagus because eosinophil distribution is patchy.
02
Esophageal biopsy histology with eosinophil count per high-power field
§ 04
Treatment & cost
medical treatments
✓Proton pump inhibitor (omeprazole 20-40 mg, esomeprazole 20-40 mg, or equivalent — twice daily for 8 weeks)
✓Budesonide orodispersible tablet (Jorveza 1 mg twice daily) — approved in Europe 2018
✓Swallowed fluticasone propionate (220-440 mcg sprayed and swallowed twice daily) — off-label
surgical options
Esophageal dilation (Savary bougie or through-the-scope balloon)Symptom relief in 75-95% of patients with fibrostenotic disease; serious complications (perforation, hospitalization) occur in under 0.5% with modern technique.
§ 05
Causes & risk factors
known causes
Type-2 immune response to dietary antigens
The dominant driver. Milk, wheat, egg, soy, peanut/tree nut, and fish/shellfish are the most common triggers. Food antigens activate a Th2 cascade in the esophageal mucosa, releasing IL-5 and IL-13, which recruit eosinophils and mast cells. Removing trigger foods reliably reverses the inflammation.
Aeroallergen exposure
Inhaled pollens, mold, and dust mite are likely cofactors. Seasonal worsening of esophageal eosinophilia mirrors local pollen counts in cohort studies, and many patients flare in spring or autumn.
Impaired esophageal epithelial barrier
Loss of filaggrin, desmoglein-1, and other barrier proteins lets antigens penetrate the mucosa. CAPN14, the EoE-associated gene with the strongest effect, encodes a protease expressed specifically in esophageal epithelium and disrupts barrier integrity when overexpressed.
Genetic susceptibility
Twin studies estimate heritability around 14-15% for monozygotic concordance, with shared family environment accounting for another large share. Implicated loci include TSLP at 5q22, CAPN14 at 2p23, LRRC32, and STAT6 — all genes in type-2 immune pathways.
Early-life environmental exposures
Antibiotic use in infancy, cesarean delivery, formula feeding, and PPI exposure in early childhood are each associated with higher EoE risk, plausibly through altered esophageal microbiome and barrier development.
Coexisting atopic disease (allergic march)
Asthma, allergic rhinitis, atopic dermatitis, and IgE-mediated food allergy share the underlying Th2 pathway. Patients with multiple atopic conditions develop EoE more often, and the same biologic targets (IL-4, IL-13) treat both.
risk factors
§ 06
Living with it
01There is no proven primary prevention strategy that stops EoE before it starts — once symptoms appear, the focus is early diagnosis and sustained remission to prevent fibrosis
02Seek endoscopic evaluation promptly for any solid-food dysphagia or food impaction; each year of diagnostic delay raises stricture risk by approximately 9%
03If you have a personal or family history of atopy and develop new upper-GI symptoms, mention EoE to your clinician — atopic background lowers the threshold for biopsy
04After histologic remission, maintain therapy long-term — withdrawal causes relapse in over 80% of adults within 12 months and risks structural progression
05Avoid eating dry, dense foods in a rushed setting if you have any history of food sticking; the most preventable acute event is food impaction
recommended foods
•Soft, moist textures (slow-cooked stews, soups, eggs prepared softly, well-cooked pasta) during active disease and immediately after dilation
•Hydration with meals — small sips of water with each bite reduce sticking risk
•Calcium- and vitamin-D-fortified alternatives when on a milk-elimination diet (fortified oat, almond, or soy beverages, plus supplementation when needed)
§ 07
When to seek help
why see a gastroenterology
Refer to gastroenterology for any adult with recurrent food impaction, progressive solid-food dysphagia, heartburn that fails 8 weeks of PPI, or suspected esophageal stricture. Children with feeding refusal, vomiting, or failure to thrive should be referred to pediatric gastroenterology. Allergy referral is appropriate when atopic comorbidities (asthma, rhinitis, eczema, IgE-mediated food allergy) need separate management. Specialist input is mandatory before starting dupilumab, before complex elimination diets, and before esophageal dilation.
01Esophageal stricture — fibrotic narrowing of the esophageal lumen causing solid-food dysphagia; develops in approximately 50% of patients diagnosed more than 10 years after symptom onset and is treated with dilation plus disease-modifying therapy
02Recurrent food impaction — the most common acute complication; carries risk of perforation when forceful retching occurs against an impacted bolus
03Esophageal perforation — rare but serious; risk is increased during forceful vomiting against a food impaction (Boerhaave syndrome) or during esophageal dilation in untreated disease (under 0.5% with modern technique)
04Small-caliber esophagus — diffuse narrowing of the whole esophagus from chronic fibrosis; identified at endoscopy or barium swallow and treated with sustained drug therapy plus dilation
Inflammatory-phenotype EoEPredominantly edema, furrows, white exudates, and rings on endoscopy without significant narrowing. More common in younger patients and in those diagnosed within a few years of symptom onset.
Fibrostenotic-phenotype EoEFixed esophageal rings, strictures, and small-caliber esophagus from submucosal fibrosis. More common with longer disease duration; each year of diagnostic delay raises stricture risk by roughly 9%.
Mixed-phenotype EoECoexisting inflammatory and fibrostenotic features — the most common adult presentation. Treatment targets both inflammation and existing narrowing.
PPI-responsive EoEHistologic and symptomatic remission with proton pump inhibitor monotherapy. Reclassified as a treatment-responsive subgroup of EoE rather than a separate disease (Molina-Infante 2018); roughly 30-50% of newly diagnosed adults respond.
Steroid-responsive EoEHistologic remission with swallowed topical corticosteroids (budesonide oral suspension, budesonide orodispersible tablet, or fluticasone). Achieves remission in 60-90% of treated patients.
Living with Eosinophilic esophagitis
Timeline
Symptom improvement on PPI, swallowed steroid, or dupilumab typically begins within 2-4 weeks. Histologic remission, the more meaningful endpoint, is assessed at 8-12 weeks of therapy by repeat endoscopy. Dietary elimination requires 6-8 weeks for full effect, with reintroduction phases adding several months and serial endoscopies. After esophageal dilation, immediate symptom improvement is common, but repeat dilations at 4-6 week intervals are often needed to reach the target esophageal diameter (typically 16-18 mm). Maintenance therapy is then continued indefinitely with surveillance endoscopy every 6-12 months until stable, then every 1-2 years.
Lifestyle
01Chew food thoroughly, eat slowly, and drink water with each bite — these behaviors reduce impaction risk independent of medical therapy
02Avoid dry, fibrous, or coarse foods (steak, dry chicken, rice, dense bread) until disease activity is controlled
03Keep an updated medical alert card listing EoE, current medications, and the contact for your gastroenterologist for use at emergency departments
04Work with a registered dietitian during any elimination phase to prevent calcium, vitamin D, iron, and B12 deficiencies — especially when eliminating milk or wheat
05Track foods, symptoms, and meals in a simple diary during reintroduction phases — patterns often emerge in the first few weeks
06Coordinate with allergy and pulmonary clinicians for asthma and rhinitis control — atopic comorbidities affect quality of life and adherence
07
Complementary approaches
Allergist-coordinated environmental allergen controlFor patients with seasonal symptom worsening tied to documented aeroallergen sensitization, standard aeroallergen avoidance and allergic rhinitis treatment may improve esophageal disease in selected cases. Adjunctive only — does not replace drug or diet therapy.
Registered-dietitian-led elimination diet supportWorking with a dietitian during elimination and reintroduction protocols improves adherence, prevents nutritional deficiencies (especially calcium and vitamin D when milk is eliminated), and roughly doubles long-term diet success in observational practice data.
Choosing a doctor
Look for a gastroenterologist with specific EoE experience — high biopsy yield (at least 6 biopsies per endoscopy), familiarity with EREFS scoring, comfort with stepwise dilation, and a working relationship with a dietitian and allergist. Centers offering EndoFLIP, formal EoE clinics, or research participation tend to deliver more consistent outcomes. In children, board-certified pediatric gastroenterology is essential because growth and feeding-development considerations differ substantially from adult care.
EOS Network (UK and Europe) →UK-based charity supporting patients with eosinophilic gastrointestinal diseases across Europe.
§ 08
Frequently asked
What is eosinophilic esophagitis?▾▴
Eosinophilic esophagitis (EoE) is a chronic immune-mediated disease in which eosinophils, a type of white blood cell, infiltrate the lining of the esophagus in response to food and aeroallergens. It causes dysphagia, food impaction, and heartburn that does not fully respond to acid-suppressing drugs. Diagnosis requires endoscopy with biopsy showing at least 15 eosinophils per high-power field.
How is eosinophilic esophagitis different from acid reflux?▾▴
Acid reflux (GERD) causes heartburn and regurgitation that typically respond fully to standard PPI therapy. EoE causes solid-food dysphagia and food impaction more than heartburn, shows characteristic rings, furrows, and exudates at endoscopy, and requires a biopsy to confirm eosinophilic inflammation. The two can coexist, and PPI-responsive eosinophilia is now considered part of the EoE spectrum rather than a separate condition.
What are the main symptoms of EoE in adults?▾▴
Adults usually present with slowly progressive solid-food dysphagia, recurrent food impaction, heartburn that does not fully resolve on PPI, and adaptive eating behaviors like drinking water with every bite or avoiding dry meats and bread. Many patients have years of subtle symptoms before diagnosis.
What are the symptoms of EoE in children?▾▴
Children present with feeding refusal, vomiting, abdominal pain, prolonged meal times, food selectivity (eating only soft textures), and failure to thrive. Older children and teenagers begin to develop the adult pattern of solid-food dysphagia and food impaction.
How is eosinophilic esophagitis diagnosed?▾▴
Diagnosis requires upper endoscopy with biopsies showing at least 15 eosinophils per high-power field in a patient with symptoms of esophageal dysfunction, after excluding other causes. The 2018 AGREE international consensus removed the prior requirement for a PPI trial before diagnosis — PPI is now considered a treatment rather than a diagnostic test.
Is eosinophilic esophagitis a food allergy?▾▴
EoE is an immune-mediated reaction to food and aeroallergens, but it is not a classical IgE-mediated food allergy. Reactions are delayed (days to weeks rather than minutes), confined to the esophagus, and standard allergy tests do not reliably predict triggers. Empiric elimination diets identify triggers more reliably than allergy testing.
What foods trigger EoE most often?▾▴
Milk is the most common trigger in both adults and children, followed by wheat, egg, and soy. Nuts and fish or shellfish are less common but possible triggers. The empiric 6-food elimination diet removes all six classes; the step-up approach starts with milk alone and adds foods sequentially.
Can EoE be cured?▾▴
EoE is not curable in the sense of permanent disease eradication, but it is highly controllable. With appropriate drug, dietary, or biologic therapy maintained long-term, histologic remission and freedom from food impaction are achievable in most patients. Withdrawal of therapy almost always leads to relapse within 6-12 months.
What is the six-food elimination diet?▾▴
The six-food elimination diet removes milk, wheat, egg, soy, nuts, and fish/shellfish for 6-8 weeks. Endoscopy confirms remission, then foods are reintroduced one at a time over months with repeat biopsies to identify the specific triggers. About 60-75% of strictly adherent patients achieve remission with this approach.
What is the step-up elimination diet?▾▴
The step-up diet starts with milk elimination alone for 6 weeks. If remission is not achieved, wheat is added (2-food); if still active, the diet expands to 4-food (milk, wheat, egg, soy). The STEP-UP trial (Kliewer 2023) showed comparable remission rates to the empiric 6-food approach with far less burden.
How does dupilumab treat EoE?▾▴
Dupilumab is a monoclonal antibody that blocks the IL-4 receptor alpha subunit, inhibiting both IL-4 and IL-13 — the key cytokines driving the type-2 inflammation in EoE. It is given as a weekly subcutaneous injection and achieved histologic remission in approximately 60% of patients at 24 weeks in the LIBERTY EoE TREET phase 3 trials (Dellon NEJM 2022).
What is Eohilia and how does it work?▾▴
Eohilia is a pre-mixed budesonide oral suspension, the first FDA-approved drug specifically for EoE (approved 2024). Patients swallow 2 mg twice daily and avoid eating or drinking for 30 minutes after each dose, allowing the steroid to coat and treat the esophageal mucosa. Histologic remission was achieved in roughly 53% at 12 weeks in pivotal trials.
What is PPI-responsive EoE?▾▴
PPI-responsive EoE is the subgroup of patients whose esophageal eosinophilia and symptoms remit on twice-daily proton pump inhibitor therapy. It was previously called a separate diagnosis (PPI-REE) but is now considered part of the EoE spectrum (Molina-Infante 2018). Roughly 30-50% of newly diagnosed adults respond to PPI alone.
Can EoE cause food impaction?▾▴
Yes. EoE is the cause of roughly 50% of adult food impactions presenting to emergency departments and is the most common cause of food impaction in adults under 50. Any adult presenting with food impaction should have biopsies taken at the endoscopy used to remove the bolus.
Does EoE increase cancer risk?▾▴
EoE does not increase the risk of esophageal cancer based on current evidence. The main complications are stricture formation and food impaction, not malignancy. Surveillance endoscopy is performed to monitor inflammation and stricture, not for cancer screening.
How often is endoscopy needed for EoE?▾▴
After diagnosis, endoscopy is repeated at 8-12 weeks of any new therapy to confirm histologic remission. Once stable, intervals stretch to every 6-12 months and then every 1-2 years for surveillance. Symptom improvement alone does not prove that eosinophilic inflammation has cleared, so periodic biopsy is essential.
Is EoE hereditary?▾▴
EoE has a strong genetic component. First-degree relatives have a roughly 10-fold higher risk, and twin studies estimate monozygotic concordance around 14-15%. Risk genes include CAPN14, TSLP, LRRC32, and STAT6, all in type-2 immune pathways. Atopic background in the family also raises individual EoE risk.
Can children grow out of EoE?▾▴
Most children do not outgrow EoE; without sustained therapy, inflammation persists into adulthood and can progress to stricture. Some pediatric patients can transition off restrictive diets onto medications during adolescence with continued surveillance, but spontaneous remission is uncommon.
Why does my heartburn medicine not fully work?▾▴
Persistent heartburn or dysphagia despite 8 weeks of standard PPI therapy is one of the most common reasons EoE is diagnosed. EoE responds partially or fully to PPI in 30-50% of adults, but the rest need swallowed topical steroids, dietary elimination, or dupilumab. Endoscopy with biopsy clarifies whether eosinophilic inflammation is the underlying driver.
What happens if EoE is left untreated?▾▴
Untreated EoE is chronic and progressive. Each year of diagnostic delay raises the risk of a fixed esophageal stricture by approximately 9%. Food impactions become more frequent, the esophagus narrows diffusely, and dilation is eventually required. EoE does not shorten life expectancy or cause cancer, but it can severely impair quality of life.
Is esophageal dilation safe in EoE?▾▴
Modern stepwise dilation (rule of 3 mm increments) is safe; serious complications such as perforation occur in under 0.5% of procedures. Post-procedural chest pain is common (roughly 75%) and usually settles within a few days. Dilation does not treat the underlying inflammation, so it is combined with drug or diet therapy.
Do I have to take EoE medication forever?▾▴
Most patients need lifelong maintenance therapy because withdrawal causes histologic and symptomatic relapse in over 80% of adults within 12 months. Long-term dosing of swallowed steroids, dupilumab, PPI, or sustained dietary elimination is similar in principle to managing asthma or atopic dermatitis.
Odynophagia (painful swallowing), especially after dry, coarse, or temperature-extreme foods.
05In children, feeding refusal, prolonged meal times, food selectivity (eating only soft or smooth textures), vomiting after meals, abdominal pain, and failure to thrive.
06Regurgitation of undigested food shortly after eating, sometimes confused with classic acid reflux.
07Nocturnal cough or aspiration episodes when retained food refluxes during sleep.
08Adaptive eating behaviors such as cutting food into small pieces, avoiding meats and bread, drinking water with every bite, or being the last person to finish a meal — often present for years before formal diagnosis.
early warning signs
•Needing to drink extra water with most meals to wash food down
•Avoiding specific textures (dry chicken, steak, rice, soft bread) for years without medical explanation
•Heartburn that responds only partially to an 8-week PPI trial
•A first episode of food sticking that resolves spontaneously after several minutes of effort
•Personal or family history of asthma, allergic rhinitis, atopic dermatitis, or food allergy in a patient with vague upper GI symptoms
● emergency signs
•Food bolus impaction — inability to swallow saliva, drooling, retrosternal pressure that does not pass within 1-2 hours; needs emergency endoscopy within 24 hours to remove the bolus and prevent perforation
•Sudden severe chest pain after vomiting or forceful retching against an impacted bolus — possible esophageal perforation (Boerhaave syndrome); imaging and surgical evaluation are urgent
•Hematemesis or melena in a patient with known EoE — bleeding from a Mallory-Weiss tear or post-impaction injury
•Sudden complete dysphagia with weight loss in an adult with longstanding EoE — concern for a tight stricture or, rarely, a coexisting esophageal cancer that warrants urgent endoscopy
Confirms the diagnosis when eosinophil count is at least 15 per high-power field. Pathology also reports basal-zone hyperplasia, lamina propria fibrosis, eosinophilic microabscesses, and surface eosinophilic layering — all supportive features.
03
EREFS endoscopic score (edema, rings, exudates, furrows, strictures)Standardized visual grading of EoE severity at endoscopy (Hirano 2013). Used to track response to therapy alongside histology and symptoms; correlates with disease activity.
04
Barium esophagram with 13 mm tablet challengeDetects subtle strictures and small-caliber esophagus not always obvious at endoscopy. Useful when dysphagia persists despite normal-appearing endoscopy.
05
Esophageal pH or pH-impedance monitoringUsed selectively to rule out coexisting GERD when histology is borderline, or to confirm acid reflux as a contributor in refractory cases. Not required for routine EoE diagnosis after the 2018 AGREE update.
06
Esophageal functional lumen imaging (EndoFLIP)Measures distensibility of the esophageal wall — reduced distensibility correlates with fibrostenotic remodeling and predicts food impaction risk. Available at specialist centers.
07
Allergy testing (skin prick, specific IgE, atopy patch testing)Not used to diagnose EoE or to direct elimination diets — allergy tests do not reliably predict food triggers in EoE. Reserved for evaluating coexisting IgE-mediated allergy and asthma comorbidities.
Outlook
With sustained treatment, the long-term outlook for EoE is excellent. Histologic remission can be achieved in 60-90% of patients on appropriate therapy and prevents progression of fibrosis. Existing strictures can be improved by esophageal dilation, and submucosal fibrosis partially reverses on long-term steroid or dupilumab therapy. Untreated, EoE is chronic and progressive — each year of unrecognized disease raises the risk of a fixed stricture by roughly 9% (Schoepfer 2013), and food impaction risk continues lifelong. EoE does not increase esophageal cancer risk, and life expectancy is normal. The major prognostic factors are time from symptom onset to diagnosis, adherence to long-term therapy, and presence of atopic comorbidities (which often need parallel treatment). After successful induction, withdrawal of therapy leads to histologic relapse in over 80% of adults within 12 months, so treatment is essentially lifelong, similar to asthma or eczema management.
Male sexnon-modifiable
Men account for roughly 70-75% of adult EoE cases — male:female ratio approximately 3:1 in most series. Reasons are unclear but parallel other Th2-driven diseases like asthma in adults.
Personal history of atopynon-modifiable
70-80% of EoE patients have asthma, allergic rhinitis, atopic dermatitis, or IgE-mediated food allergy. Atopic dermatitis in infancy especially raises later EoE risk.
Family history of EoE or atopygenetic
First-degree relatives have a roughly 10-fold higher EoE risk; sibling concordance is around 2.3%. Familial clustering reflects both shared genes and shared early-life environment.
White ethnicitynon-modifiable
EoE is more common in non-Hispanic white populations in North America and Europe, though the disease occurs in every ethnic group and may be underdiagnosed elsewhere.
Northern latitude and dry climateenvironmental
Higher EoE incidence has been documented in colder, drier US states and northern European countries — possibly mediated by aeroallergen patterns or vitamin D status.
Early antibiotic and PPI exposuremodifiable
Antibiotic use during infancy is associated with 2-4x higher childhood EoE risk; PPI exposure in early childhood also rises with risk. Both may alter esophageal microbiome and barrier maturation.
Cesarean delivery and lack of breastfeedingmodifiable
Both modestly raise EoE risk in case-control studies, likely through effects on the early microbiome.
EoE prevalence is markedly elevated in connective-tissue disorders, suggesting shared pathways involving TGF-beta signaling.
•Whole-grain alternatives such as rice, quinoa, oats, and corn during wheat elimination
•Lean protein from sources outside the trigger list — chicken, turkey, beef, legumes (depending on which foods are being eliminated)
•Plenty of cooked vegetables, fruits, and well-tolerated fats from olive oil, avocado, and seeds
foods to avoid
•Specific trigger foods identified by elimination and reintroduction endoscopies — most commonly milk and wheat in adults; milk in children
•Dry, dense, coarse, or hard foods (tough meats, dense bread, rice cakes, raw carrots) until inflammation and any strictures are controlled
•Very hot or very cold liquids during a flare — temperature extremes can trigger spasm in an inflamed esophagus
•Alcohol if it provokes heartburn or reflux symptoms; reflux superimposed on EoE worsens mucosal injury
•Large meals immediately before lying down — combined reflux and dysphagia increases nocturnal aspiration risk
•Unprescribed antihistamines, leukotriene receptor antagonists, or oral cromolyn as solo EoE therapy — none have proven benefit
Nutritional deficiencies during restrictive elimination diets — calcium, vitamin D, iron, B12 — preventable with dietitian-led planning and selective supplementation
06Quality-of-life and psychosocial impact — eating-related anxiety, social withdrawal, and meal avoidance are common and often underrecognized; respond to dietitian and behavioral support
choosing the right hospital
01Gastroenterology service with same-day upper endoscopy capacity, including 24-hour access for food impaction
02Pathology laboratory experienced in eosinophil counting and EREFS-aligned reporting
03Access to esophageal dilation expertise (Savary bougie and balloon techniques)
04Dietitian familiar with empiric elimination and reintroduction protocols
05Allergy and immunology service for atopic comorbidity management
06EndoFLIP or high-resolution manometry availability for refractory cases
Avoid alcohol and large late-evening meals if reflux is a coexisting problem; reflux can amplify esophageal inflammation
Daily management
01Take swallowed topical steroid at the same time daily, and do not eat or drink for 30 minutes after each dose to maximize esophageal contact time
02Use an asthma spacer correctly if you also have asthma — and remember that swallowed fluticasone for EoE is sprayed without a spacer and swallowed, not inhaled
03Plan meals with adequate time for slow eating, especially in social or work settings where rushing causes impaction
04Keep at least one short course of liquid antihistamine or topical anesthetic spray prescribed for transient throat discomfort, if your clinician recommends
05Schedule the surveillance endoscopy that confirms remission — symptom relief alone does not prove inflammation has cleared
06Carry hospital paperwork showing the diagnosis and last endoscopy date when traveling — useful if a food impaction needs emergency care abroad
Exercise
Regular physical activity is encouraged and is not restricted by EoE itself. Avoid heavy exertion immediately after a meal if reflux is a factor; otherwise normal exercise is safe even during active disease.